Search Results - "Post, Dawn"

Mps1 Mediated Phosphorylation of Hsp90 Confers Renal Cell Carcinoma Sensitivity and Selectivity to Hsp90 Inhibitors by Woodford, Mark R., Truman, Andrew W., Dunn, Diana M., Jensen, Sandra M., Cotran, Richard, Bullard, Renee, Abouelleil, Mourad, Beebe, Kristin, Wolfgeher, Donald, Wierzbicki, Sara, Post, Dawn E., Caza, Tiffany, Tsutsumi, Shinji, Panaretou, Barry, Kron, Stephen J., Trepel, Jane B., Landas, Steve, Prodromou, Chrisostomos, Shapiro, Oleg, Stetler-Stevenson, William G., Bourboulia, Dimitra, Neckers, Len, Bratslavsky, Gennady, Mollapour, Mehdi

“…The molecular chaperone Hsp90 protects deregulated signaling proteins that are vital for tumor growth and survival. Tumors generally display sensitivity and…”
Get full text

Gravin regulates centrosome function through PLK1 by Colicino, Erica G, Garrastegui, Alice M, Freshour, Judy, Santra, Peu, Post, Dawn E, Kotula, Leszek, Hehnly, Heidi

“…We propose to understand how the mitotic kinase PLK1 drives chromosome segregation errors, with a specific focus on Gravin, a PLK1 scaffold. In both…”
Get full text

PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma by YUAN RONG, POST, Dawn E, PIEPER, Russell O, DURDEN, Donald L, VAN MEIR, Erwin G, BRAT, Daniel J

“…We have previously proposed that intravascular thrombosis and subsequent vasoocclusion contribute to the development of pseudopalisading necrosis, a pathologic…”
Get full text

Abi1 loss drives prostate tumorigenesis through activation of EMT and non-canonical WNT signaling by Nath, Disharee, Li, Xiang, Mondragon, Claudia, Post, Dawn, Chen, Ming, White, Julie R, Hryniewicz-Jankowska, Anita, Caza, Tiffany, Kuznetsov, Vladimir A, Hehnly, Heidi, Jamaspishvili, Tamara, Berman, David M, Zhang, Fan, Kung, Sonia H Y, Fazli, Ladan, Gleave, Martin E, Bratslavsky, Gennady, Pandolfi, Pier Paolo, Kotula, Leszek

“…Prostate cancer development involves various mechanisms, which are poorly understood but pointing to epithelial mesenchymal transition (EMT) as the key…”
Get full text

Use of Replicating Oncolytic Adenoviruses in Combination Therapy for Cancer by CHU, Roland L, POST, Dawn E, KHURI, Fadlo R, VAN MEIR, Erwin G

“…Oncolytic virotherapy is the use of genetically engineered viruses that specifically target and destroy tumor cells via their cytolytic replication cycle…”
Get full text

Geldanamycin induces degradation of hypoxia-inducible factor 1α protein via the proteosome pathway in prostate cancer cells by MABJEESH, Nicola J, POST, Dawn E, WILLARD, Margaret T, KAUR, Balveen, VAN MEIR, Erwin G, SIMONS, Jonathan W, HUA ZHONG

Get full text

A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy by POST, Dawn E, VAN MEIR, Erwin G

“…New therapy targeting the hypoxic fraction of tumors needs to be designed as this population of cells is the most resistant to radio- and chemotherapies…”
Get full text

Targeted cancer gene therapy using a hypoxia inducible factor-dependent oncolytic adenovirus armed with interleukin-4 by POST, Dawn E, SANDBERG, Eric M, KYLE, Michele M, DEVI, Narra Sarojini, BRAT, Daniel J, ZHIHENG XU, TIGHIOUART, Mourad, VAN MEIR, Erwin G

“…There is a need for novel therapies targeting hypoxic cells in tumors. These cells are associated with tumor resistance to therapy and express hypoxia…”
Get full text

Replicative oncolytic herpes simplex viruses in combination cancer therapies by Post, Dawn E, Fulci, Giulia, Chiocca, E Antonio, Van Meir, Erwin G

“…Viruses that kill the host cell during their replication cycle have attracted much interest for the specific killing of tumor cells and this oncolytic…”
Get more information

Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models by Longo, Sharon L., Padalino, David J., McGillis, Sandra, Petersen, Kirstin, Schirok, Hartmut, Politz, Oliver, Canute, Gregory W., Post, Dawn E.

“…Summary The epidermal growth factor receptor (EGFR) pathway is aberrantly activated in tumors and plays a key role in promoting tumor growth. Small molecule…”
Get full text

Cancer Therapy with a Replicating Oncolytic Adenovirus Targeting the Hypoxic Microenvironment of Tumors by POST, Dawn E, NARRA SAROJINI DEVI, ZHENCHAO LI, BRAT, Daniel J, KAUR, Balveen, NICHOLSON, Ainsley, OLSON, Jeffrey J, ZHAOBIN ZHANG, VAN MEIR, Erwin G

“…Hypoxia plays a critical role in driving tumor malignancy and is associated with poor patient survival in many human cancers. Novel therapies targeting hypoxic…”
Get full text

Replicative oncolytic adenoviruses in multimodal cancer regimens by Post, Dawn E, Khuri, Fadlo R, Simons, Jonathan W, Van Meir, Erwin G

“…The use of replication-competent viruses that have a cytolytic cycle has emerged as a viable strategy (oncolytic virotherapy) to specifically kill tumor cells…”
Get more information

Cancer scene investigation: how a cold virus became a tumor killer by Post, Dawn E, Shim, Hyunsuk, Toussaint-Smith, Esra, Van Meir, Erwin G

“…Oncolytic therapy is a novel anticancer treatment with attenuated lytic viruses such as adenovirus (Ad). These viruses kill the host cells through their lytic…”
Get more information

Abstract 1088: Defining bone metastatic potential of Abi1 CRISPR prostate cancer cell lines by Nappi, Alexander, Post, Dawn, Das, Disharee, Joshi, Ishita, Oest, Megan, Bratslavsky, Gennady, Kotula, Leszek

“…Abstract Prostate cancer is the second most common cancer in American men, and it is the third leading cause of cancer-related deaths in American men. Distant…”
Get full text

Abstract 4466: The key role of Abi1 loss in dysregulating cell-cell adhesion during prostate cancer tumorigenesis by Das, Disharee, Hryniewicz-Jankowska, Anita, Hehnly, Heidi, Post, Dawn, Bratslavsky, Gennady, Kotula, Leszek

“…Abstract Prostate cancer accounts for 20-25% of cancer cases every year and is predicted at over 180,000 new cases in 2016. However, the mechanisms of prostate…”
Get full text

Abstract 1403: Modeling of Abi1 loss using spheroid cultures to investigate mechanisms of prostate tumorigenesis by Das, Disharee, Chen, Ming, Mondragon, Claudia, Post, Dawn, Nappi, Alexander, Hehnly, Heidi, Hryniewicz-Jankowska, Anita, Pandolfi, Pier Paolo, Bratslavsky, Gennady, Kotula, Leszek

“…Abstract American Cancer Society predicts over 160,000 new prostate cancer cases in 2017, which amounts to about 20 percent of all cancer diagnoses in men…”
Get full text

Abi1 loss drives prostate tumorigenesis through activation of EMT and noncanonical WNT signaling by Nath, Disharee, Li, Xiang, Mondragon, Claudia, Post, Dawn, Chen, Ming, Hryniewicz-Jankowska, Anita, Caza, Tiffany, White, Julie, Kuznetsov, Vladimir, Hehnly, Heidi, Khanna, Rakesh, Gleicher, Stephanie, Jamaspishvili, Tamara, Berman, David Monty, Zhang, Fan, Kung, Sonia H.Y., Fazli, Ladan, Bratslavsky, Gennady, Pandolfi, Pier Paolo, Kotula, Leszek

“…Abstract only 280 Background: Prostate cancer is characterized by heterogeneity of mechanisms which are poorly understood but pointing to epithelial plasticity…”
Get full text

Genetic and hypoxic regulation of angiogenesis in gliomas by Kaur, Balveen, Tan, Chalet, Brat, Daniel J, Post, Dawn E, Van Meir, Erwin G

“…Infiltrative astrocytic neoplasms are by far the most common malignant brain tumors in adults. Clinically, they are highly problematic due to their widely…”
Get full text

Abstract 586: Targeted cancer gene-therapy using second-generation HIF-activated oncolytic adenoviruses with increased replication, oncolytic, and anti-tumor efficacy by Cherry, Tiffani, Longo, Sharon, Magee, Amanda, Tovar-Spinoza, Zulma, Post, Dawn E.

“…Abstract A clinically important target for anti-tumor therapy is hypoxia-inducible factor (HIF). HIF is a transcription factor that is expressed in a wide…”
Get full text

Second-generation HIF-activated oncolytic adenoviruses with improved replication, oncolytic, and anti-tumor efficacy by Cherry, Tiffani, Longo, Sharon L., Tovar-Spinoza, Zulma, Post, Dawn E.

“…There is a need to develop more potent oncolytic adenoviruses that exhibit increased anti-tumor activity in patients. The HYPR-Ads are targeted oncolytic…”
Get full text